Skip to main content

Advertisement

Open Peer Review Reports for: Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg ® ) in children with relapsed/refractory myeloid leukemia

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
14 Feb 2006 Submitted Original manuscript
1 May 2006 Reviewed Reviewer Report - Frederick Appelbaum
6 Jun 2006 Author responded Author comments - Benoit Brethon
Resubmission - Version 2
6 Jun 2006 Submitted Manuscript version 2
13 Jun 2006 Author responded Author comments - Benoit Brethon
Resubmission - Version 3
13 Jun 2006 Submitted Manuscript version 3
16 Jun 2006 Author responded Author comments - Benoit Brethon
Resubmission - Version 4
16 Jun 2006 Submitted Manuscript version 4
Publishing
28 Jun 2006 Editorially accepted
28 Jun 2006 Article published 10.1186/1471-2407-6-172

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement